Stuart Bell

Executive Vice President - Inceptua Early Access.

[Stuart Bell @InceptuaAccess]

Inceptua Early Access will be participating in @BiotechWkBoston from 18-21 September. If you have an interest in Expanded Access, Early Access, Compassionate Use, or any other form of specialised medicine distribution, then please connect to meet up.

[Rare Anaemias International Network @rareanaemias]

📣 September is #SickleCellAwarenessMonth! 📣

Patients with #sicklecelldisease have abnormal haemoglobin (called haemoglobin S), which can change red blood cells into a sickle or crescent shape.

Help increase awareness and share this post! @SCDAAorg @SickleCellUK #rarenaemias

[Stuart Bell @InceptuaAccess]

Across Europe there is disparity in the average time for new drugs to be approved and accessible to patients.

For an orphan drug, the delay between centralised European Medicines Agency approval and in-country commercial availabi…https://t.co/RuNy99aWLa https://t.co/aiOi45ydjC

[Stuart Bell @InceptuaAccess]

Given the current focus on #preapproval access due to COVID-19, we thought this would be a good opportunity to review #preapproval access with industry expert @PaulAliu2000 https://t.co/LvMUT8FpY9

[Stuart Bell @InceptuaAccess]

Please do take a look at the webinar for some fantastic insights on #Preapproval access from @PaulAliu2000

[Inceptua - Pharma Company and Service Partner @InceptuaGroup]

Access our latest webinar #ondemand https://t.co/6kl42nuWdz and learn more about #ExpandedAccess as a Key Component in the #Drugdevelopment and #Launch Process #preapprovalaccess

[Stuart Bell @InceptuaAccess]

Great article, Neil! Something like this has been coming down the line for some time. Concerning for patients. Let's hope a pragmatic approach is taken. #preapprovalaccess #expandedaccess https://t.co/VBRsHxWtoa

[The Journal of Medicine Access @Medicine_Access]

Patients and physicians are wanting access to approved orphan drugs but access can still take 12-18 months in some EU countries. @ME_Corbett @InceptuaGroup @orphan_drugs #WorldOrphanDrugCongress #MedicineAccess #MarketAccess

[Stuart Bell @InceptuaAccess]

https://t.co/GbQcn08jWA

[Stuart Bell @InceptuaAccess]

Looking forward to EA3 https://t.co/U6bXFdA3oT @Expanded_Access and discussing access to medicines with the leaders in this space.

[Expanded Access Summit @Expanded_Access]

EA Summit Faculty member, @StuartBMAC on early access to #RareDisease treatment in Europe. #expandedaccess #clinicaltrials https://t.co/xcIYt70PDC

[Stuart Bell @InceptuaAccess]

Uncharted waters: Navigating requests for experimental medicines https://t.co/OEPwATO4jA via @bcmhouston Pleased to see a focus on neuro-oncology in expanded access. Not sure I agree much with the issues around clinical trials and ethics though. But keen to follow developments.

[Stuart Bell @InceptuaAccess]

11% of planned clinical trials fail to enrol a single patient. #rarediseasesummit

[Stuart Bell @InceptuaAccess]

Best pre-approval conference by far. #expandedaccesssummit #expandedaccess

[Stuart Bell @InceptuaAccess]

https://t.co/HFBLDya1SK

[Expanded Access Summit @Expanded_Access]

Excellent piece on global #ExpandedAccess pathways by EA Summit faculty member, Dr. Stuart Bell. Hear him live at the annual event, Expanded Access 3.0, Jan. 27-29, 2020 in Washington DC. https://t.co/LyxIWz0Gyc

[Stuart Bell @InceptuaAccess]

https://t.co/ydgwIvCqxm

[Stuart Bell @InceptuaAccess]

https://t.co/qrWRQg6eYJ

[Stuart Bell @InceptuaAccess]

Brilliant @JAMAOnc paper on single patient use #expandedaccess at @mskcc by Hyman et. al. 36.1% of products were in Phase 2, 39.4% in Phase 3, and an incredible 18.8% were in Phase 1. Authors call for routine prospective collection of efficacy data in expanded access. Fully agree

[Stuart Bell @InceptuaAccess]

An exciting new service to allow pharma and biotech a 'safe harbor' to explore how #preapprovalaccess or #expandedaccess may work for them. No obligation. No pressure. Just impartial, expert advice. Free-of-charge. https://t.co/Jf1TRTbmsa

[Stuart Bell @InceptuaAccess]

https://t.co/UBsmoFtIq6

[Stuart Bell @InceptuaAccess]

https://t.co/907xzeu9GI